Literature DB >> 18071931

[Implantation technique for the CUT-type femoral neck endoprosthesis].

Maximilian Rudert1, Ulf Leichtle, Carmen Leichtle, Wolfram Thomas.   

Abstract

OBJECTIVE: Total hip replacement with maximum preservation of femoral neck. Restoration of pain-free joint function. INDICATIONS: Coxarthrosis, femoral head necrosis in younger patients with intact femoral neck. CONTRAINDICATIONS: Joint infection. Coxa valga (caput-collum-diaphysis [CCD] angle > 150 degrees ). Coxa vara (CCD angle < 110 degrees ). Body mass index > 30 (relative contraindication). Ongoing chemotherapy. Osteoporosis. SURGICAL TECHNIQUE: Transgluteal or anterolateral approach. Resection of two thirds of the femoral head. Implantation of uncemented acetabular component. Revitalization of the femoral neck with special rasps for the CUT prosthesis. Trial reduction with bone rasp and modular cone in place (10 degrees or 20 degrees angle). Uncemented stem implantation.
RESULTS: From 2002 to 2006, 49 uncemented CUT prostheses were implanted in 36 patients. Average age was 45.1 years (20-60 years). Inpatient stay amounted to 10.8 days and operating time to 74 min. Average blood loss through drainage was 795 ml, an average of 297 ml transfused back. Transfusion was necessary in ten patients. There were no cases of postoperative infection, nerve lesion, or hip dislocation. Patients were examined preoperatively and followed up at 6 weeks and 1 year. Harris Hip Score improved from 46.1 points preoperatively to 81.6 points at 6 weeks and 95.7 points at 1 year. Average leg length discrepancy of 0.7 cm (minimum -0.8, maximum 2.2 cm) was determined radiologically in 31 of 49 patients. It became necessary to replace two of the 49 stems due to aseptic loosening, in the first case at 19 months (femoral head osteonecrosis, lupus erythematosus, and taking cortisone), and in the second case 3 years after implantation (steroid-induced femoral head necrosis related to Crohn's disease and azathioprine [Imurek] therapy). One cone and head component had to be revised 1 month after implantation due to impingement syndrome. One ceramic head fractured 2.5 years after implantation so that cone and head required revision. The overall follow-up time was 37 months on average (minimum 12, maximum 55 months).

Entities:  

Mesh:

Year:  2007        PMID: 18071931     DOI: 10.1007/s00064-007-1018-4

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  6 in total

1.  [Muscle trauma in primary total hip arthroplasty depending on age, BMI, and surgical approach: minimally invasive anterolateral versus modified direct lateral approach].

Authors:  M Müller; S Tohtz; M Dewey; I Springer; C Perka
Journal:  Orthopade       Date:  2011-03       Impact factor: 1.087

2.  Uncemented short stems in primary total hip arthroplasty: The state of the art.

Authors:  Mattia Loppini; Guido Grappiolo
Journal:  EFORT Open Rev       Date:  2018-05-09

3.  Femoral neck prostheses: A systematic analysis of the literature.

Authors:  Stefanos Tsitlakidis; Fabian Westhauser; Axel Horsch; Nicholas Beckmann; Rudi Bitsch; Matthias Klotz
Journal:  Orthop Rev (Pavia)       Date:  2019-09-24

4.  5-year clinical and radiostereometric analysis (RSA) follow-up of 39 CUT femoral neck total hip prostheses in young osteoarthritis patients.

Authors:  Marc J Nieuwenhuijse; Edward R Valstar; Rob G H H Nelissen
Journal:  Acta Orthop       Date:  2012-08-10       Impact factor: 3.717

5.  Bone mineral density after implantation of a femoral neck hip prosthesis--a prospective 5 year follow-up.

Authors:  Wolfram Steens; Friedrich Boettner; Rainer Bader; Ralf Skripitz; Alberto Schneeberger
Journal:  BMC Musculoskelet Disord       Date:  2015-08-12       Impact factor: 2.362

Review 6.  Revision rate after short-stem total hip arthroplasty: a systematic review of 49 studies.

Authors:  Jakob van Oldenrijk; Jeroen Molleman; Michel Klaver; Rudolf W Poolman; Daniel Haverkamp
Journal:  Acta Orthop       Date:  2014-04-03       Impact factor: 3.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.